Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma Guide

To find a commercial service, choose an option from the Main Category below or Search by Company Name.

Approvals Action
New hope for metabolic disease
Alexion's orphan therapy Kanuma has been approved by the TGA for metabolic disease lysomal acid lipase deficiency.
Pipeline Monitor
Pfizer sets Xeljanz for psoriatic arthritis
Pfizer has filed Janus kinase inhibitor Xeljanz with the FDA in the hopes of a second indication in psoriatic arthritis for the star drug.
Debating Point
PBAC reform could be best of new agreement
The wider effects of the new agreement between the government and Medicines Australia will not be seen until proposed PBAC reforms become a reality.